Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Therapeutic Targeting of the Unfolded Protein Response in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 December 2019.
In recent years, endoplasmic reticulum (ER) proteostasis has been identified as a major player in cancer. In particular, the signaling mechanisms that are involved in ER proteostasis maintenance were shown to significantly contribute to cancer hallmarks such as epithelial-to-mesenchymal transition (EMT), inflammation, migration/invasion, or resistance to therapy. These signaling mechanisms are collectively assembled under the name of unfolded protein response (UPR) and transduced by three ER resident proteins named IRE1, PERK, and ATF6. The role of IRE1 and PERK in cancer development and their relevance as therapeutic targets in the disease have clearly been documented, whereas the role of ATF6 in oncogenesis or treatment resistance remains less clear.
In the past five years, a large number of pharmacological or genetic approaches targeting the three arms of the UPR were developed to be applied as therapeutics in various diseases, including cancer.
In this Special Issue, we aim at providing (i) state-of-the-art reviews on the current knowledge regarding the pharmacological and genetic tools that were developed to selectively target ATF6, PERK, IRE1 or UPR regulators, as well as their reported utilizations in cancer models; (ii) research articles describing novel pharmacological molecules or genetic tools targeting IRE1, PERK, ATF6 or any other UPR regulators, as well as their potential use in cancer models; and finally, (iii) novel preclinical results with UPR targeting drugs.
Dr. Eric Chevet
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.